Royalty Pharma Net Income 2019-2024 | RPRX

Royalty Pharma net income for the twelve months ending June 30, 2024 was $0.673B, a 164.07% increase year-over-year.

  • Royalty Pharma annual net income for 2023 was $1.135B, a 2549.5% increase from 2022.
  • Royalty Pharma annual net income for 2022 was $0.043B, a 93.09% decline from 2021.
  • Royalty Pharma annual net income for 2021 was $0.62B, a 36.44% decline from 2020.

Royalty Pharma Net Income 2019-2024 | RPRX

  • Royalty Pharma annual net income for 2023 was $1.135B, a 2549.5% increase from 2022.
  • Royalty Pharma annual net income for 2022 was $0.043B, a 93.09% decline from 2021.
  • Royalty Pharma annual net income for 2021 was $0.62B, a 36.44% decline from 2020.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$207.9B
Blackstone (BX)$127.3B
Moody's (MCO)$83.6B
Synchrony Financial (SYF)$26.3B
Brookfield Asset Management (BAM)$25.3B
Orix Corp Ads (IX)$25.3B
Grupo Financiero Banorte SAB De CV (GBOOY)$20.8B
Equitable Holdings (EQH)$15.8B
Jefferies Financial Group (JEF)$14.8B
Houlihan Lokey (HLI)$13.1B
SoFi Technologies (SOFI)$12.6B
Globe Life (GL)$10B
XP (XP)$9.9B
Daiwa Securities Group (DSEEY)$9.6B
Jackson Financial (JXN)$8.6B
SouthState (SSB)$8.5B
Brookfield Wealth Solutions (BNT)$8.3B
StepStone Group (STEP)$7.3B
Lazard (LAZ)$6.9B
Freedom Holding (FRHC)$6.4B
Blue Owl Capital (OBDC)$5.9B
Rithm Capital (RITM)$5.5B
Virtu Financial (VIRT)$5.2B
Upstart Holdings (UPST)$4.8B
AXOS FINANCIAL, INC (AX)$4.7B
Euronet Worldwide (EEFT)$4.5B
PJT Partners (PJT)$3.9B
HA Sustainable Infrastructure Capital (HASI)$3.8B
Community Financial System (CBU)$3.7B
Core Scientific (CORZ)$3.7B